Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Development of Vancomycin Initial Dosage Guidelines to Achieve New Target Ranges

Vancomycin 초기 투여 용량 개선 방안

  • Received : 2010.10.04
  • Accepted : 2010.11.18
  • Published : 2010.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

In 2009, American Journal of Health-System Pharmacy (AJHP) recommended that targeting vancomycin trough concentrations of 10 mg/L or more because of therapeutic failure and potential risk of developing vancomycin resistance. Therefore, new dosage guidelines that could achieve to these higher target were needed. The aims of this study were to develop dosage guidelines targeting new vancomycin trough concentration and to evaluate the performance of these new guidelines. All data analysis were performed using NONMEM(R). Population pharmacokinetic model was first developed from vancomycin dosage and concentration data collected retrospectively during routine therapeutic drug monitoring in 441 patients, then new vancomycin dosage guidelines were developed by using the model to predict vancomycin trough and peak concentrations in a simulated dataset. The estimates, such as, vancomycin concentration trough level, time to achieve target level, mean error were performed to evaluate and compare difference between conventional dosage and new dosage guidelines. The proposed dosage guidelines were predicted to achieve 43.5% of vancomycin trough level within 10~20 mg/L, which is significantly higher than current guidelines (26.3%). Time to achieve target trough level was 19.4 hours in new guidelines comparing to 93.1 hours in the conventional dosage. Thus, new vancomycin dosage guidelines have been developed to achieve new target trough concentrations earlier and more consistently than conventional guidelines.

Keywords

References

  1. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42(suppl 1): S3-4. https://doi.org/10.1086/491708
  2. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42(suppl 1): S35-39. https://doi.org/10.1086/491712
  3. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501. https://doi.org/10.1016/S0891-5520(03)00065-5
  4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10. https://doi.org/10.1086/516284
  5. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nature Rev Microbiol 2004; 2: 289-300. https://doi.org/10.1038/nrmicro862
  6. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006; 119(6, suppl 1): S37-44. https://doi.org/10.1016/j.amjmed.2006.04.001
  7. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al., Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus if predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-1705. https://doi.org/10.1086/421092
  8. Geraci J. Vancomycin. Mayo Clin Proc 1977; 52: 631-634.
  9. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquried, ventilator-associated, and healthcareassociated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-955. https://doi.org/10.1378/chest.130.4.947
  10. Boffi El, Amari E, Vuagnat A, et al., High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis 2004; 36: 712-717
  11. Moore MR, Perdreau-Remington F, Chamers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Stapylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-1266. https://doi.org/10.1128/AAC.47.4.1262-1266.2003
  12. Rybak M, Lomaestro B, Rotschafer JC, et al., Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Diseases Pharmasists. Am J Health-Syst Pharm 2009; 66: 82-98. https://doi.org/10.2146/ajhp080434
  13. Sakoulas G, Gold HS, Cohen RA, et al., Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus(MRSA) in a patient with recurrent bacteremia. J Antimicrob Chemother 2006; 57: 699-704. https://doi.org/10.1093/jac/dkl030
  14. Howden BP, Ward PB, Charles PG, et al., Treatment outcomes of serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8. https://doi.org/10.1086/381202
  15. Joint Formulary Committee : British National Formulary, Fifty-sixth Edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2008.
  16. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients: the Optivanco study. Antimicrob Agents Chemother 2009; Feb 17. https://doi.org/10.1128/AAC.01149-08
  17. Thomson AH, Staatz CE, Tobin CM, et al., Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; Mar 19. https://doi.org/10.1093/jac/dkp085
  18. Michael EW. Basic Clinical Pharmacokinetics, 4th ed. New York: Lippincott Williams & Wilkins, 2004; 451-476.
  19. Matzke GR, McGory RW, Halstenson CE, et al., Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 1984; Apr: 433-437. https://doi.org/10.1128/AAC.25.4.433
  20. Yasuhara M, Iga T, Zenda H, et al., Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit 1998; 20: 139-148. https://doi.org/10.1097/00007691-199804000-00003
  21. Rodvold KA, Blum RA, Fischer JH, et al., Vancomycin pharmacokinetics in patients with varying degrees of renal function. Antimicorb Agents Chemother 1988; 32: 848- 852. https://doi.org/10.1128/AAC.32.6.848
  22. Wang JT, Fang CT, Chen YC, et al., Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 2001. 47: 239-246. https://doi.org/10.1093/jac/47.2.239